ATYPICAL RESPONDERS LANDSCAPE REVIEW ∙ OCTOBER, 2017 48 81. Nagourney, R.A., et al., Functional profiling to select chemotherapy in untreated, advanced or metastatic non-small cell lung cancer. Anticancer Res, 2012. 32(10): p. 4453-60. 82. Frenkel, M., et al., Activism among exceptional patients with cancer. Support Care Cancer, 2011. 19(8): p. 1125-32. 83. Frenkel, M., et al., Living outliers: experiences, insights and narratives of exceptional survivors of incurable cancer. Future Oncol, 2015. 11(12): p. 1741-9. 84. Tichy, J.R., et al., Race, response to chemotherapy, and outcome within clinical breast cancer subtypes. Breast Cancer Res Treat, 2015. 150(3): p. 667-74. 85. Patel, T.A., et al., Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups. Oncologist, 2010. 15(5): p. 466-75. 86. Bailey, A.M., et al., Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. Discov Med, 2014. 17(92): p. 101-14. 87. Jiang, Y., et al., Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. Oncotarget, 2013. 4(6): p. 884-9. 88. Jiang, Y., et al., Novel secondary somatic mutations in Ewing’s sarcoma and desmoplastic small round cell tumors. PLoS One, 2014. 9(8): p. e93676. 89. Van Allen, E.M., et al., Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol, 2015. 1(2): p. 238-44.